Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Camzyos

CAMZYOS 2.5 mg hard capsules CAMZYOS 5 mg hard capsules CAMZYOS 10 mg hard capsules CAMZYOS 15 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11–12

HOS-147609 · Präparat HOS-099694

11 Concomitant CYP2C19 poor metaboliser phenotype* CYP2C19 intermediate, medicinal product normal, rapid and ultra-rapid metaboliser phenotype Weak CYP2C19 No dose adjustment. Monitor LVEF 4 weeks Initiating or increasing the dose inhibitor (e.g., later, and then resume the patient’s monitoring of a weak inhibitor while on cimetidine, citalopram, and titration schedule. Adjust mavacamten mavacamten treatment: omeprazolea, dose based on clinical assessment (see Monitor LVEF 4 weeks later, esomeprazole) section 4.2). and subsequently resume the patient’s monitoring and titration schedule. Adjust mavacamten dose based on clinical assessment (see section 4.2). Weak CYP3A4 inhibitor If on medication when starting mavacamten, Initiating or increasing the dose (e.g., cimetidine, no adjustment of the starting dose of 2.5 mg is of a weak inhibitor while on esomeprazole, needed. mavacamten treatment: omeprazole, No dose adjustment. Monitor pantoprazole) Initiating or increasing the dose of weak LVEF 4 weeks later, and then inhibitor while on mavacamten treatment: resume the patient’s monitoring If patients are receiving a 5 mg dose of and titration schedule. Adjust mavacamten, their dose should be reduced to mavacamten dose based on 2.5 mg or if on 2.5 mg pause treatment for clinical assessment (see 4 weeks. section 4.2). Monitor LVEF 4 weeks later, and then resume the patient’s monitoring and titration schedule (see section 4.2). Inducers Strong CYP2C19 Initiating or increasing the dose of strong Initiating or increasing the dose inducer and strong inducer while on mavacamten treatment: of strong inducer while on CYP3A4 inducer (e.g., Monitor LVOT gradient and LVEF 4 weeks mavacamten treatment: rifampicin, apalutamide, later. Adjust mavacamten dose based on Monitor LVOT gradient and enzalutamide, mitotane, clinical assessment and then resume the LVEF 4 weeks later. Adjust phenytoin, patient’s monitoring and titration schedule mavacamten dose based on carbamazepine, (see section 4.2). The maximum dose is 5 mg. clinical assessment and then efavirenz, St. John’s resume the patient’s monitoring wort) Discontinuing or decreasing the dose of and titration schedule (see strong inducer while on mavacamten section 4.2). treatment: Decrease mavacamten dose from 5 mg to Discontinuing or decreasing the 2.5 mg or pause treatment if on 2.5 mg. dose of strong inducer while on Monitor LVEF 4 weeks later, and then resume mavacamten treatment: the patient’s monitoring and titration schedule Decrease mavacamten by one (see section 4.2). dose level when on doses 5 mg or higher. Maintain mavacamten dose when on 2.5 mg. Monitor LVEF 4 weeks later, and then resume the patient’s monitoring and titration schedule (see section 4.2).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) esomeprazole (HOS-087944) cimetidine (HOS-085835) carbamazepine (HOS-085618) apalutamide (HOS-086212) pantoprazole (HOS-085167) mitotane (HOS-112479) efavirenz (HOS-087947) phenytoin (HOS-084531) enzalutamide (HOS-116829) omeprazole (HOS-085912)